SAT-305 EFFECTS OF EMPAGLIFLOZIN VS PLACEBO ON CARDIORENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOME